{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:37:39Z","timestamp":1791916659764,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.antiviral.2014.01.016","type":"journal-article","created":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T19:32:06Z","timestamp":1391283126000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"special_numbering":"C","title":["Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment"],"prefix":"10.1016","volume":"104","author":[{"given":"Dionna","family":"Scharton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Vest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna B.","family":"Westover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohichi","family":"Kumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Van Wettere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.01.016_b0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF01310749","article-title":"Pathogenesis of a phleboviral infection (Punta Toro virus) in golden Syrian hamsters","volume":"114","author":"Anderson","year":"1990","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2014.01.016_b0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1001\/jama.287.18.2391","article-title":"Hemorrhagic fever viruses as biological weapons: medical and public health management","volume":"287","author":"Borio","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.antiviral.2014.01.016_b0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3851\/IMP1729","article-title":"Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir","volume":"21","author":"Buys","year":"2011","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.antiviral.2014.01.016_b0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.antiviral.2007.11.002","article-title":"Treatment of Crimean\u2013Congo hemorrhagic fever","volume":"78","author":"Ergonul","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.01.016_b0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4269\/ajtmh.2003.69.269","article-title":"Induction of severe disease in hamsters by two sandfly fever group viruses, Punta Toro and Gabek Forest (Phlebovirus, Bunyaviridae), similar to that caused by Rift Valley fever virus","volume":"69","author":"Fisher","year":"2003","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2014.01.016_b0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.01.016_b0035","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.01.016_b0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2013.03.009","article-title":"Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge","volume":"98","author":"Gowen","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.01.016_b0045","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.01.016_b0050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2009.10.015","article-title":"Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models","volume":"86","author":"Gowen","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.01.016_b0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of action of ribavirin against distinct viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2014.01.016_b0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of Rift Valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2014.01.016_b0065","doi-asserted-by":"crossref","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5\u2032-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.antiviral.2014.01.016_b0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.antiviral.2011.02.003","article-title":"Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB\/c mouse model by stinging nettle lectin, Urtica dioica agglutinin","volume":"90","author":"Kumaki","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.01.016_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2008.01.004","article-title":"Molecular strategies to inhibit the replication of RNA viruses","volume":"78","author":"Leyssen","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.01.016_b0080","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2014.01.016_b0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1124\/mol.113.087247","article-title":"Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)","volume":"84","author":"Naesens","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2014.01.016_b0090","first-page":"197","article-title":"Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters","volume":"92","author":"Niklasson","year":"1984","journal-title":"Acta Pathol. Microbiol. Immunol. Scand [C]"},{"key":"10.1016\/j.antiviral.2014.01.016_b0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0166-3542(86)90024-0","article-title":"Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator","volume":"6","author":"Peters","year":"1986","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.01.016_b0100","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0882-4010(87)90011-8","article-title":"Punta Toro virus infection of C57BL\/6J mice: a model for phlebovirus-induced disease","volume":"3","author":"Pifat","year":"1987","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.antiviral.2014.01.016_b0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.antiviral.2014.01.016_b0110","doi-asserted-by":"crossref","first-page":"e2156","DOI":"10.1371\/journal.pntd.0002156","article-title":"Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development","volume":"7","author":"Reed","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.antiviral.2014.01.016_b0115","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.antiviral.2014.01.016_b0120","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2174\/092986706778773059","article-title":"Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research","volume":"13","author":"Russmann","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2014.01.016_b0125","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/AAC.00886-13","article-title":"Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome","volume":"57","author":"Safronetz","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.01.016_b0130","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of Action of T-705 ribosyl triphosphate against influenza virus RNA polymerase","volume":"57","author":"Sangawa","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.01.016_b0135","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.virol.2010.08.016","article-title":"The pathogenesis of Rift Valley fever virus in the mouse model","volume":"407","author":"Smith","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2014.01.016_b0140","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14656566.2.8.1317","article-title":"Ribavirin \u2013 current status of a broad spectrum antiviral agent","volume":"2","author":"Snell","year":"2001","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400028X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421400028X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T06:51:01Z","timestamp":1565160661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421400028X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":28,"alternative-id":["S016635421400028X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.016","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}